Embecta Corp. (EMBC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a global diabetes care and medical supplies company. As an issuer listed on The Nasdaq Global Select Market, embecta’s SEC filings cover topics such as financial performance, governance, compensation, and material corporate events.
On this page, you can review current reports on Form 8-K, where embecta discloses items like quarterly and full-year financial results, dividend declarations, and changes to its board of directors. For example, the company has used Form 8-K to report earnings for specific quarters and fiscal years, and to describe director departures and planned leadership changes on the board.
Embecta also files a definitive proxy statement on Schedule 14A, which outlines proposals for its annual meeting of stockholders, including the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and amendments to equity-based compensation plans. The proxy statement provides information on board composition, committee structures, director skills and experience, and governance practices.
In addition to these filings, investors can access embecta’s annual and quarterly reports referenced in its proxy materials, which contain audited financial statements, segment and product family revenue breakdowns, and discussions of strategic priorities such as strengthening the core business, expanding the product portfolio, and increasing financial flexibility.
Stock Titan’s platform enhances these regulatory disclosures with AI-powered summaries that highlight key points from lengthy documents, helping readers understand the implications of embecta’s 8-Ks, proxy statements, and other filings. Real-time updates from EDGAR, combined with structured access to forms related to governance and financial reporting, allow users to follow how embecta’s strategy, board decisions, and financial performance are reflected in its official SEC record.
Embecta Corp. Schedule 13G filed reporting passive institutional holdings by Yacktman entities. Yacktman Asset Management LP is reported as beneficial owner of 3,671,877 shares (6.20%) and AMG Yacktman Fund holds 3,000,000 shares (5.07%). The filing states voting and dispositive powers held by the Adviser and identifies the Adviser’s address and CUSIP 29082k105.
The filing attributes shared voting and disposal power to the Adviser under Rule 13d-3 and is signed by authorized representatives with signature dates of 05/05/2026.
Embecta Corp. Schedule 13G filed reporting passive institutional holdings by Yacktman entities. Yacktman Asset Management LP is reported as beneficial owner of 3,671,877 shares (6.20%) and AMG Yacktman Fund holds 3,000,000 shares (5.07%). The filing states voting and dispositive powers held by the Adviser and identifies the Adviser’s address and CUSIP 29082k105.
The filing attributes shared voting and disposal power to the Adviser under Rule 13d-3 and is signed by authorized representatives with signature dates of 05/05/2026.
Embecta Corp. reported weaker results for the quarter ended March 31, 2026, as revenue fell to $221.8 million from $259.0 million, a 14.4% decline. Lower volumes and pricing pressure, especially in pen needles and U.S. markets, reduced gross margin to 57.6% from 63.4% and turned net income of $23.5 million into a net loss of $4.1 million (basic EPS $(0.07)).
For the first six months, revenue declined to $483.0 million, but net income improved to $40.0 million helped by sharply lower restructuring and patch pump-related charges and a $10.1 million gain on asset sales. Operating income for the half rose to $118.3 million.
The company remains highly leveraged with total principal debt of $1.34 billion and a weighted-average interest rate of 6.1%, though it prepaid $75.0 million on its term loan. Embecta agreed to acquire UK-based Owen Mumford for up to £150 million, launched a three-year $100.0 million share repurchase plan, and sharply cut its quarterly dividend from $0.15 to $0.01 per share to conserve cash.
Embecta Corp. reported weaker results for the quarter ended March 31, 2026, as revenue fell to $221.8 million from $259.0 million, a 14.4% decline. Lower volumes and pricing pressure, especially in pen needles and U.S. markets, reduced gross margin to 57.6% from 63.4% and turned net income of $23.5 million into a net loss of $4.1 million (basic EPS $(0.07)).
For the first six months, revenue declined to $483.0 million, but net income improved to $40.0 million helped by sharply lower restructuring and patch pump-related charges and a $10.1 million gain on asset sales. Operating income for the half rose to $118.3 million.
The company remains highly leveraged with total principal debt of $1.34 billion and a weighted-average interest rate of 6.1%, though it prepaid $75.0 million on its term loan. Embecta agreed to acquire UK-based Owen Mumford for up to £150 million, launched a three-year $100.0 million share repurchase plan, and sharply cut its quarterly dividend from $0.15 to $0.01 per share to conserve cash.
Embecta reported weak second quarter fiscal 2026 results and cut its full-year outlook. Q2 revenues were $221.8 million, down 14.4%, with U.S. revenue falling 29.4% and international revenue up slightly on a reported basis. Gross margin declined to 57.6%, and the company posted a net loss of $4.1 million, or $(0.07) per diluted share, versus net income of $23.5 million and $0.40 a year earlier. Adjusted EPS was $0.27, down from $0.70.
For the first six months, revenue was $483.0 million, down 7.3%, with net income of $40.0 million and adjusted EPS of $0.98. Embecta now guides fiscal 2026 revenue to $1,015–$1,035 million and adjusted EPS to $1.55–$1.75, both sharply lower than prior guidance. The updated outlook assumes ongoing U.S. headwinds and includes the pending Owen Mumford acquisition, expected to add about $30 million of revenue and reduce adjusted EPS by roughly $0.15.
The board authorized a three-year $100 million share repurchase program and cut the quarterly dividend from $0.15 to $0.01 per share, reallocating cash toward repurchases and debt reduction. Management still expects to repay about $150 million of debt in 2026. As of March 31, 2026, the company held $193.4 million in cash and equivalents and restricted cash and had $1.342 billion of debt principal outstanding, with no borrowings on its $500 million revolver.
Embecta reported weak second quarter fiscal 2026 results and cut its full-year outlook. Q2 revenues were $221.8 million, down 14.4%, with U.S. revenue falling 29.4% and international revenue up slightly on a reported basis. Gross margin declined to 57.6%, and the company posted a net loss of $4.1 million, or $(0.07) per diluted share, versus net income of $23.5 million and $0.40 a year earlier. Adjusted EPS was $0.27, down from $0.70.
For the first six months, revenue was $483.0 million, down 7.3%, with net income of $40.0 million and adjusted EPS of $0.98. Embecta now guides fiscal 2026 revenue to $1,015–$1,035 million and adjusted EPS to $1.55–$1.75, both sharply lower than prior guidance. The updated outlook assumes ongoing U.S. headwinds and includes the pending Owen Mumford acquisition, expected to add about $30 million of revenue and reduce adjusted EPS by roughly $0.15.
The board authorized a three-year $100 million share repurchase program and cut the quarterly dividend from $0.15 to $0.01 per share, reallocating cash toward repurchases and debt reduction. Management still expects to repay about $150 million of debt in 2026. As of March 31, 2026, the company held $193.4 million in cash and equivalents and restricted cash and had $1.342 billion of debt principal outstanding, with no borrowings on its $500 million revolver.
Embecta Corp. ownership amendment: American Century Capital Portfolios, American Century Investment Management, American Century Companies and Stowers Institute filed an Amendment No. 4 to report beneficial ownership of Common Stock.
The filing lists 1,997,167 shares (3.4%) for American Century Capital Portfolios and 3,439,512 shares (5.8%) for American Century Investment Management / American Century Companies / Stowers Institute, with signatures dated 05/01/2026.
Embecta Corp reports that Vanguard Capital Management beneficially owns 3,004,501 shares of Common Stock, representing 5.07% of the class. The filer reports 440,550 shares with sole voting power and 3,004,501 shares with sole dispositive power. The filing is signed by Ashley Grim on 04/29/2026.
Embecta Corp — The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting zero beneficial ownership of Embecta Corp common stock, listing 0 shares and 0% ownership. The filing states this reporting change follows an internal realignment of Vanguard and related subsidiaries in accordance with SEC Release No. 34-39538.
The amendment identifies Vanguard's separate reporting by subsidiaries and notes that The Vanguard Group, Inc. no longer is deemed to have beneficial ownership over securities held by those subsidiaries. The form is signed by a Vanguard official on 03/26/2026.
Embecta Corp. has agreed to acquire UK-based medical device maker Owen Mumford Holdings Limited in a transaction valued at up to £150 million. Embecta will pay £100 million in cash at closing, plus up to £50 million in additional payments tied to net sales of the Aidaptus® auto-injector platform through the three-year period following closing.
Owen Mumford generated net revenue of £69.4 million during its fiscal year 2025 and brings a portfolio of drug-delivery and chronic care devices that complement Embecta’s diabetes-focused franchise. Embecta expects the deal to support revenue growth from fiscal year 2027 onward, be accretive to adjusted operating income after fiscal year 2027, and generate a high-single-digit return on invested capital by year four.
The transaction, unanimously approved by Embecta’s board, is structured as a share acquisition for 100% of Owen Mumford’s equity and is expected to close in Embecta’s fiscal third quarter of 2026, subject to regulatory approvals and customary conditions. Embecta plans to fund the upfront purchase price with borrowings under its revolving credit facility.
Anderson Carrie L reported acquisition or exercise transactions in a Form 4 filing for EMBC. The filing lists transactions totaling 22,841 shares. Following the reported transactions, holdings were 64,581 shares.
HOMBACH ROBERT J. reported acquisition or exercise transactions in this Form 4 filing.
Embecta Corp. director Robert J. Hombach received an award of 22,841 shares of Embecta common stock on February 11, 2026 at a grant price of $0.00 per share. Following this grant, he directly beneficially owns 64,587.208 shares, which the filing notes include shares received as stock dividends.
Embecta Corp. director Morris Milton Mayo reported acquiring 22,841 shares of Embecta common stock on February 11, 2026. The shares were received as a grant or similar award at a price of $0.00 per share, meaning no cash was paid for the acquisition. Following this transaction, Mayo directly beneficially owns 60,121.34 Embecta common shares. The reported total includes shares that were received as stock dividends, so it reflects both prior holdings and dividend-related share accruals.